Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026)
Definium Therapeutics' (DFTX) quarterly Other Non-Current Assets came in at $812000.0 in Q1 2026, up 33.99% year-on-year from $606000.0 in Q1 2025, and down 5.8% on a QoQ basis from $862000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 5 years of Other Non-Current Assets data on file, last reported at $812000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 33.99% year-over-year to $812000.0 in Q1 2026; TTM through Mar 2026 was $812000.0, a 33.99% increase from a year earlier, with the FY2025 full-year figure at $862000.0, up 40.62% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $812000.0, down from $862000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for DFTX reached as high as $1.2 million in Q2 2025 and fell as low as $144000.0 in Q1 2024.
- Historically, Other Non-Current Assets has averaged $552857.1 across 5 years, with a median of $513500.0 in 2024.
- Across the five-year window, Other Non-Current Assets tumbled 52.0% in 2024 and soared 320.83% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $331000.0 in 2022, then sank by 32.33% to $224000.0 in 2023, then jumped by 173.66% to $613000.0 in 2024, then soared by 40.62% to $862000.0 in 2025, then decreased by 5.8% to $812000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $812000.0 in Q1 2026, $862000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Definium Therapeutics | 4.47 Bn | 4.47 Bn | - | 812,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 812,000.00 |
| Dec 31, 2025 | 862,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 229,000.00 |
| Jun 30, 2023 | 268,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 331,000.00 |